These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1451 related articles for article (PubMed ID: 30926722)
1. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Fanouriakis A; Kostopoulou M; Alunno A; Aringer M; Bajema I; Boletis JN; Cervera R; Doria A; Gordon C; Govoni M; Houssiau F; Jayne D; Kouloumas M; Kuhn A; Larsen JL; Lerstrøm K; Moroni G; Mosca M; Schneider M; Smolen JS; Svenungsson E; Tesar V; Tincani A; Troldborg A; van Vollenhoven R; Wenzel J; Bertsias G; Boumpas DT Ann Rheum Dis; 2019 Jun; 78(6):736-745. PubMed ID: 30926722 [TBL] [Abstract][Full Text] [Related]
2. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Fanouriakis A; Kostopoulou M; Andersen J; Aringer M; Arnaud L; Bae SC; Boletis J; Bruce IN; Cervera R; Doria A; Dörner T; Furie RA; Gladman DD; Houssiau FA; Inês LS; Jayne D; Kouloumas M; Kovács L; Mok CC; Morand EF; Moroni G; Mosca M; Mucke J; Mukhtyar CB; Nagy G; Navarra S; Parodis I; Pego-Reigosa JM; Petri M; Pons-Estel BA; Schneider M; Smolen JS; Svenungsson E; Tanaka Y; Tektonidou MG; Teng YO; Tincani A; Vital EM; van Vollenhoven RF; Wincup C; Bertsias G; Boumpas DT Ann Rheum Dis; 2024 Jan; 83(1):15-29. PubMed ID: 37827694 [TBL] [Abstract][Full Text] [Related]
3. [EULAR recommendations 2023 on the treatment of systemic lupus erythematosus -Implications for treatment in Germany]. Mucke J; Aringer M Z Rheumatol; 2024 Aug; 83(6):431-438. PubMed ID: 39037547 [TBL] [Abstract][Full Text] [Related]
4. Update οn the diagnosis and management of systemic lupus erythematosus. Fanouriakis A; Tziolos N; Bertsias G; Boumpas DT Ann Rheum Dis; 2021 Jan; 80(1):14-25. PubMed ID: 33051219 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of systemic lupus erythematosus: myths, certainties and doubts]. Ruiz-Irastorza G; Danza A; Khamashta M Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892 [TBL] [Abstract][Full Text] [Related]
6. Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Aringer M; Burkhardt H; Burmester GR; Fischer-Betz R; Fleck M; Graninger W; Hiepe F; Jacobi AM; Kötter I; Lakomek HJ; Lorenz HM; Manger B; Schett G; Schmidt RE; Schneider M; Schulze-Koops H; Smolen JS; Specker C; Stoll T; Strangfeld A; Tony HP; Villiger PM; Voll R; Witte T; Dörner T Lupus; 2012 Apr; 21(4):386-401. PubMed ID: 22072024 [TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy of systemic lupus erythematosus associated peripheral neuropathy: A systematic review. Constantin A; Năstase D; Tulbă D; Bălănescu P; Băicuș C Lupus; 2020 Oct; 29(12):1509-1519. PubMed ID: 32757735 [TBL] [Abstract][Full Text] [Related]
9. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Staveri C; Karokis D; Liossis SC Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432 [TBL] [Abstract][Full Text] [Related]
11. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Ugarte A; Danza A; Ruiz-Irastorza G Curr Opin Rheumatol; 2018 Sep; 30(5):482-489. PubMed ID: 29870497 [TBL] [Abstract][Full Text] [Related]
12. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. Fasano S; Coscia MA; Pierro L; Ciccia F Lupus; 2021 May; 30(6):991-997. PubMed ID: 33709836 [TBL] [Abstract][Full Text] [Related]
14. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Danve A; Perry L; Deodhar A Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336 [TBL] [Abstract][Full Text] [Related]
16. [What is new in the treatment of Systemic Lupus Erythematosus?]. Skácelová M Vnitr Lek; 2022; 68(5):273-278. PubMed ID: 36283816 [TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481 [TBL] [Abstract][Full Text] [Related]
18. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Andreoli L; Bertsias GK; Agmon-Levin N; Brown S; Cervera R; Costedoat-Chalumeau N; Doria A; Fischer-Betz R; Forger F; Moraes-Fontes MF; Khamashta M; King J; Lojacono A; Marchiori F; Meroni PL; Mosca M; Motta M; Ostensen M; Pamfil C; Raio L; Schneider M; Svenungsson E; Tektonidou M; Yavuz S; Boumpas D; Tincani A Ann Rheum Dis; 2017 Mar; 76(3):476-485. PubMed ID: 27457513 [TBL] [Abstract][Full Text] [Related]
19. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Kuhn A; Bonsmann G; Anders HJ; Herzer P; Tenbrock K; Schneider M Dtsch Arztebl Int; 2015 Jun; 112(25):423-32. PubMed ID: 26179016 [TBL] [Abstract][Full Text] [Related]
20. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]